18F-FPPRGD2 PET/CT 在转移性肾细胞癌患者中的应用
本前瞻性 pilot 研究纳入 7 例转移性肾细胞癌(mRCC)患者,按病灶分析比较 18F-FPPRGD2 与 18F-FDG PET/CT,并评估抗血管生成治疗前后参数变化。抗血管生成治疗后 18F-FPPRGD2 的 SUVmax 与 T/B 均下降。提示 18F-FPPRGD2 PET/CT 可能有助于监测 mRCC 抗血管生成治疗的早期反应,但需更大样本验证。
要点
- 18F-FPPRGD2 PET/CT 的 SUVmax 低于 18F-FDG PET/CT(4.4±2.9 对 7.8±5.6,P<0.001)。
- 抗血管生成治疗后 18F-FPPRGD2 的 SUVmax 与 T/B 均下降。
- 18F-FPPRGD2 PET/CT 可能用于监测 mRCC 抗血管生成治疗的早期反应。
核心结论
- 18F-FPPRGD2 PET/CT 可能是监测 mRCC 患者抗血管生成治疗早期反应的有用工具,但初步结果需更大队列确认。
研究设计与样本
- 前瞻性 pilot 研究纳入 7 例转移性肾细胞癌患者,按病灶分析比较 18F-FPPRGD2 与 18F-FDG PET/CT,并测量抗血管生成治疗前后的 SUVmax 与肿瘤/本底比值(T/B)。
主要发现
- 抗血管生成治疗开始后,18F-FPPRGD2 PET/CT 的 SUVmax 下降(4.2±3.2 对 2.6±1.4,P=0.003)。
- 抗血管生成治疗开始后,18F-FPPRGD2 PET/CT 的 T/B 下降(3.7±3.2 对 1.5±0.8,P<0.001)。
- SUVmax 与 T/B 的平均变化分别为 -29.3±23.6% 与 -48.1±28.3%。
临床怎么用
- 在 mRCC 患者接受抗血管生成治疗时,可考虑用 18F-FPPRGD2 PET/CT 的 SUVmax 与 T/B 变化辅助评估早期治疗反应。
局限性
- 本研究为 pilot 研究,仅纳入 7 例患者,初步结果需在更大队列中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The usefulness of positron emission tomography/computed tomography (PET/CT) using (18F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (18F-FPPRGD2) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study. METHODS: Seven patients with mRCC were enrolled in this prospective study. 18F-FPPRGD2 and 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUVmax) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy. RESULTS: Sixty lesions in total were detected in this cohort. SUVmax from 18F-FPPRGD2 PET/CT was lower than that from 18F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUVmax and T/B from 18F-FPPRGD2 PET/CT decreased after starting antiangiogenic therapy (SUVmax, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUVmax and T/B were - 29.3 ± 23.6% and - 48.1 ± 28.3%, respectively. CONCLUSIONS: 18F-FPPRGD2 PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.
引用
- Toriihara A, Duan H, Thompson HM, et al. 18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 30850872. doi:10.1007/s00259-019-04295-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。